AEON BIOPHARMA, INC. INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification and Advancement Agreement • October 4th, 2021 • AEON Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification and Advancement Agreement (“Agreement”) is made as of, 2020 by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • October 4th, 2021 • AEON Biopharma, Inc. • Pharmaceutical preparations • California
This Settlement and License Agreement (“Agreement”) made and entered into as of June 21, 2021 (the “Effective Date”), by and between, on the one hand Medytox, Inc. (“Medytox”) a company duly organized and existing under the laws of South Korea, having its principal office at 78 Gangni 1-gil Ochang-up Cheongwon-gu Cheongju-si North Chungcheong 28126, Republic of South Korea, and, on the other hand, AEON Biopharma, Inc., (“AEON”) a company duly organized and existing under the laws of Delaware, having its principal office at 4040 MacArthur Boulevard, Suite 260, Newport Beach, CA 92660 (each individually a “Party,” and collectively the “Parties”).
LICENSE & SUPPLY AGREEMENTSupply Agreement • October 4th, 2021 • AEON Biopharma, Inc. • Pharmaceutical preparations
THIS LICENSE AND SUPPLY AGREEMENT (hereinafter this “Agreement”) is entered into this 20th day of December, 2019 (the “Effective Date”), by and between Daewoong Pharmaceutical Co., Ltd, a corporation organized and existing under the laws of the Republic of Korea, having its main office at Bongeunsaro 114-gil 12, Gangnam-gu, Seoul 06170 (hereinafter “DAEWOONG”); and AEON Biopharma, Inc., a corporation organized and existing under the laws of Delaware, United States, having its main office at 4040 MacArthur Blvd, Newport Beach, CA, USA 92660 (hereinafter “AEON”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 4th, 2021 • AEON Biopharma, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (this “Agreement”), dated as of [______], 2021, is between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Chris Carr, an individual (“Employee”), effective as of [______], 20211 (the “Amended Effective Date”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 4th, 2021 • AEON Biopharma, Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (this “Agreement”), dated as of [______], 2021, is between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Marc Forth, an individual (“Employee”), effective as of [______], 20211 (the “Amended Effective Date”).
AEON BIOPHARMA, INC. AMENDMENT TO SUBORDINATED CONVERTIBLE PROMISSORY NOTEAEON Biopharma, Inc. • October 4th, 2021 • Pharmaceutical preparations
This Amendment (this “Amendment”) to the Subordinated Convertible Promissory Note, as defined below, is made as of May 10, 2021 (the “Effective Date”), by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceutical Co., Ltd., a company organized and existing under the laws of the Republic of Korea (the “Holder”). Capitalized terms used but not otherwise defined herein shall have the same meanings as set forth in the Note Purchase Agreement, as defined below, or the Original Note, as applicable.
AEON BIOPHARMA, INC. FIRST AMENDMENT TO THE THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • October 4th, 2021 • AEON Biopharma, Inc. • Pharmaceutical preparations • Delaware
This First Amendment to the Third Amended and Restated Investors’ Rights Agreement (this “Amendment”), is made and entered into as of October 2, 2021, by and among AEON Biopharma, Inc. (f/k/a Alphaeon Corporation, the “Company”) and the Investors signatory hereto.
